RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
C4 Therapeutics Stock

C4 Therapeutics P/E 2025

C4 Therapeutics P/E

-1.24

Ticker

CCCC

ISIN

US12529R1077

As of Feb 12, 2025, C4 Therapeutics's P/E ratio was -1.24, a -43.38% change from the -2.19 P/E ratio recorded in the previous year.

The C4 Therapeutics P/E history

C4 Therapeutics Aktienanalyse

What does C4 Therapeutics do?

The company C4 Therapeutics Inc. was founded in 2015 and is headquartered in Watertown, Massachusetts. The company specializes in the development of drugs that work based on targeted protein degradation. This approach aims to specifically break down proteins in the body that are associated with various diseases. C4 Therapeutics develops special molecules that bind to these proteins and help break them down. The company's business model is based on collaboration with other companies in the pharmaceutical industry, where they develop drug candidates and license them to other companies for further development and marketing. C4 Therapeutics has a specialized strategy to become a leader in the field of targeted protein degradation. They are currently active in various areas, including the development of cancer drugs with a focus on proteins responsible for tumor growth, as well as neurology drugs for diseases like Alzheimer's and Parkinson's. Their important development is the PROTAC platform technology, which allows targeted protein degradation by binding two different molecules to the protein, triggering a cascade of reactions that lead to protein breakdown. Overall, C4 Therapeutics is an innovative and dynamic company specializing in drug development based on targeted protein degradation, with promising potential to treat a range of diseases. Despite being relatively young, the company has already achieved numerous successes and is expected to play an important role in the pharmaceutical industry in the future. C4 Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering C4 Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of C4 Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing C4 Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of C4 Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in C4 Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about C4 Therapeutics stock

What is the price-to-earnings ratio of C4 Therapeutics?

The price-earnings ratio of C4 Therapeutics is currently -1.24.

How has the price-earnings ratio of C4 Therapeutics changed compared to last year?

The price-to-earnings ratio of C4 Therapeutics has increased by -43.38% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of C4 Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of C4 Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of C4 Therapeutics affect the company?

An increase in the price-earnings ratio of C4 Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of C4 Therapeutics affect the company?

A decrease in the price-earnings ratio of C4 Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of C4 Therapeutics?

Some factors that influence the price-earnings ratio of C4 Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does C4 Therapeutics pay?

Over the past 12 months, C4 Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, C4 Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of C4 Therapeutics?

The current dividend yield of C4 Therapeutics is .

When does C4 Therapeutics pay dividends?

C4 Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of C4 Therapeutics?

C4 Therapeutics paid dividends every year for the past 0 years.

What is the dividend of C4 Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is C4 Therapeutics located?

C4 Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von C4 Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of C4 Therapeutics from 2/12/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 2/12/2025.

When did C4 Therapeutics pay the last dividend?

The last dividend was paid out on 2/12/2025.

What was the dividend of C4 Therapeutics in the year 2024?

In the year 2024, C4 Therapeutics distributed 0 USD as dividends.

In which currency does C4 Therapeutics pay out the dividend?

The dividends of C4 Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von C4 Therapeutics

Our stock analysis for C4 Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of C4 Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.